Harrow Health Publishes Corporate Transparency Report
NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company’s website, harrowinc.com. The report focuses on Harrow Health’s commitment to initiatives that it believes support its mission to make innovative, sight-saving medications more accessible and affordable.
“I am pleased to present our 2022 Corporate Transparency Report, which we believe demonstrates action we have taken to develop sustainable business practices and to positively impact local communities and the lives of our customers and employees. Simply put, this is a report card of why each member of the Harrow family is proud to be a part of what we do each and every day,” said Mark L. Baum, Chief Executive Officer of Harrow Health. “We have always placed the highest emphasis on innovation, quality, and safety that produces medicines that solve real‑world, unmet patient needs; personal and professional integrity and inclusivity that encourages a collaborative and mutually supportive culture; and a dedication for serving our customers in a way that adheres to the highest ethical standards.
“We continue to refine and develop new initiatives that represent Harrow Health’s commitment to respecting the environment, supporting our stakeholders and exhibiting strong corporate governance. We want our stakeholders to know that these principles, which have been a part of our DNA from our founding, are of paramount importance to Harrow Health, including an active and engaged Board of Directors, executive team and employees. We are committed to transparency and accountability throughout our company, which we believe will create long‑term value for all stakeholders.”
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic vision care. Harrow Health also holds non‑controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical‑stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, www.harrowinc.com.
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the impact of the COVID-19 pandemic and any future health epidemics on our financial condition, liquidity and results of operations; our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; market acceptance of the Company’s formulations and challenges related to the marketing of the Company’s formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Jamie Webb, Director of Communications and IR